JPWO2022140774A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022140774A5 JPWO2022140774A5 JP2023537498A JP2023537498A JPWO2022140774A5 JP WO2022140774 A5 JPWO2022140774 A5 JP WO2022140774A5 JP 2023537498 A JP2023537498 A JP 2023537498A JP 2023537498 A JP2023537498 A JP 2023537498A JP WO2022140774 A5 JPWO2022140774 A5 JP WO2022140774A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- amino acid
- protein
- constant domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 claims 17
- 102000004169 proteins and genes Human genes 0.000 claims 16
- 150000001413 amino acids Chemical class 0.000 claims 8
- 239000003550 marker Substances 0.000 claims 7
- 230000035772 mutation Effects 0.000 claims 6
- 230000002068 genetic effect Effects 0.000 claims 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 101100096028 Mus musculus Smok1 gene Proteins 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- -1 IL- 27 Proteins 0.000 claims 1
- 102100026720 Interferon beta Human genes 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 108700026244 Open Reading Frames Proteins 0.000 claims 1
- 102220501600 Putative uncharacterized protein UNQ6493/PRO21345_Y37F_mutation Human genes 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 1
- 238000006722 reduction reaction Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063129480P | 2020-12-22 | 2020-12-22 | |
| US63/129,480 | 2020-12-22 | ||
| US202163170196P | 2021-04-02 | 2021-04-02 | |
| US63/170,196 | 2021-04-02 | ||
| PCT/US2021/073057 WO2022140774A1 (en) | 2020-12-22 | 2021-12-21 | Peptide markers to track genetically engineered cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023554674A JP2023554674A (ja) | 2023-12-28 |
| JPWO2022140774A5 true JPWO2022140774A5 (https=) | 2024-12-20 |
| JP2023554674A5 JP2023554674A5 (https=) | 2024-12-20 |
Family
ID=80218522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023537498A Pending JP2023554674A (ja) | 2020-12-22 | 2021-12-21 | 遺伝子改変細胞追跡用ペプチドマーカー |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220195006A1 (https=) |
| EP (1) | EP4267606A1 (https=) |
| JP (1) | JP2023554674A (https=) |
| KR (1) | KR20230124983A (https=) |
| AU (1) | AU2021410077A1 (https=) |
| CA (1) | CA3202874A1 (https=) |
| IL (1) | IL303809A (https=) |
| MX (1) | MX2023007445A (https=) |
| TW (1) | TW202241937A (https=) |
| WO (1) | WO2022140774A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4192941A1 (en) | 2020-08-07 | 2023-06-14 | Neogene Therapeutics B.V. | Methods to enrich genetically engineered t cells |
| EP4635976A1 (en) * | 2024-04-19 | 2025-10-22 | Medigene Immunotherapies GmbH | Constant uni-tabs |
| WO2025219541A1 (en) * | 2024-04-19 | 2025-10-23 | Medigene Immunotherapies Gmbh | Constant uni-tabs |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1878744A1 (en) * | 2006-07-13 | 2008-01-16 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Epitope-tag for surface-expressed T-cell receptor proteins, uses thereof and method of selecting host cells expressing them |
| WO2016079333A1 (en) * | 2014-11-20 | 2016-05-26 | Umc Utrecht Holding B.V. | Use of antibodies for enrichment of engineered t cells with exogenous immune receptors and antibodies for use in depletion of engineered t cells |
| CN110352068A (zh) * | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
| RU2761377C2 (ru) | 2017-04-03 | 2021-12-07 | Ф. Хоффманн-Ля Рош Аг | Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15 |
| AU2018345400B2 (en) * | 2017-10-05 | 2024-06-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for selectively expanding cells expressing a TCR with a murine constant region |
| EP3946382A1 (en) * | 2019-04-04 | 2022-02-09 | UMC Utrecht Holding B.V. | Modified immune receptor constructs |
-
2021
- 2021-12-21 US US17/557,514 patent/US20220195006A1/en active Pending
- 2021-12-21 CA CA3202874A patent/CA3202874A1/en active Pending
- 2021-12-21 EP EP21854791.7A patent/EP4267606A1/en active Pending
- 2021-12-21 JP JP2023537498A patent/JP2023554674A/ja active Pending
- 2021-12-21 TW TW110147984A patent/TW202241937A/zh unknown
- 2021-12-21 MX MX2023007445A patent/MX2023007445A/es unknown
- 2021-12-21 KR KR1020237024600A patent/KR20230124983A/ko active Pending
- 2021-12-21 WO PCT/US2021/073057 patent/WO2022140774A1/en not_active Ceased
- 2021-12-21 AU AU2021410077A patent/AU2021410077A1/en active Pending
- 2021-12-21 IL IL303809A patent/IL303809A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhu | T helper cell differentiation, heterogeneity, and plasticity | |
| Parronchi et al. | Effects of interferon‐α on cytokine profile, T cell receptor repertoire and peptide reactivity of human allergen‐specific T cells | |
| Gallagher et al. | Human interleukin-19 and its receptor: a potential role in the induction of Th2 responses | |
| Vieira et al. | Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. | |
| Assenmacher et al. | Sequential production of IL‐2, IFN‐γ and IL‐10 by individual staphylococcal enterotoxin B‐activated T helper lymphocytes | |
| Sun et al. | NK cells and immune “memory” | |
| Wakao et al. | Expansion of functional human mucosal-associated invariant T cells via reprogramming to pluripotency and redifferentiation | |
| Noma et al. | Enhancement of the interleukin 2 receptor expression on T cells by multiple B-lymphotropic lymphokines | |
| Flowers et al. | A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease | |
| Romagnani | The Th1/Th2 paradigm and allergic disorders. | |
| Panzer et al. | Rapid in vivo conversion of effector T cells into Th2 cells during helminth infection | |
| Legge et al. | Coupling of peripheral tolerance to endogenous interleukin 10 promotes effective modulation of myelin-activated T cells and ameliorates experimental allergic encephalomyelitis | |
| Fleischer et al. | Clonal analysis of infiltrating T lymphocytes in liver tissue in viral hepatitis A | |
| Yamada et al. | Features of the cytokines secreted by adult T cell leukemia (ATL) cells | |
| KR970702367A (ko) | 보호성 면역 반응 및 IL-12 생산의 자극과 증강을 위한 화합물 및 방법(Compounds and methods for the stimulation and enhancement of protective immune responses and IL-12 production) | |
| Choi et al. | Molecular and functional characterization of chickenIL-15 | |
| NZ241321A (en) | Cancer treatment, method of cultivating tumour-infiltrating lymphocytes | |
| KR20000010799A (ko) | 억제인자 세포 집단을 생성시키기 위한 인터루킨-10의 용도 | |
| KR20080111054A (ko) | 신규한 인간 ｔ세포 집단 | |
| Hegazy et al. | Plasticity and lineage commitment of individual TH1 cells are determined by stable T-bet expression quantities | |
| JPWO2022140774A5 (https=) | ||
| Amills et al. | Cytokine mRNA expression in B cells from bovine leukemia virus-infected cattle with persistent lymphocytosis | |
| Curran et al. | Nucleotide sequence of the equine interferon gamma cDNA | |
| Tang et al. | Differential induction of T cell cytokine mRNA in Epstein‐Barr virus‐transformed B cell clones: constitutive and inducible expression of interleukin‐4 mRNA | |
| Xiao et al. | The CD8 T cell response to vaccinia virus exhibits site-dependent heterogeneity of functional responses |